Physician profile
Ali Madani
NPI 1952374464
$6,634.99
in general payments reported to CMS, 2019-2025
35 companies · $62.62 in 2025
The $62.62 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,547 · 2020: $207 · 2021: $267 · 2022: $61.07 · 2023: $1,702 · 2024: $788 · 2025: $62.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,552.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spectrum Pharmaceuticals INC. | $3,204.66 | 2019 | |
| Exelixis INC. | $1,520.02 | 2023-2024 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $302.65 | 2019-2024 | |
| Incyte Corporation | $188.26 | 2020-2024 | Jakafi |
| Glaxosmithkline, LLC. | $161.52 | 2020-2025 | Ojjaara, Jemperli |
| Janssen Biotech, INC. | $153.49 | 2019-2024 | Darzalex, Akeega, Erleada |
| Celgene Corporation | $140.48 | 2021 | |
| Tg Therapeutics, INC. | $114.27 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $85.78 | 2023-2024 | Imfinzi, Lynparza, Tagrisso |
| Eisai INC. | $85.58 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $80.96 | 2019-2022 | |
| Abbvie INC. | $55.69 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $55.41 | 2019-2020 | |
| Gilead Sciences, INC. | $41.59 | 2022-2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $39.89 | 2023-2024 | Xpovio |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $36.41 | 2023-2024 | Monoferric |
| Seagen INC. | $32.22 | 2023 | Tukysa, Adcetris |
| Alexion Pharmaceuticals, INC. | $32.12 | 2024 | Ultomiris |
| Genzyme Corporation | $29.99 | 2024 | |
| Pfizer INC. | $27.31 | 2019-2023 | |
| Genmab U.S., INC. | $26.12 | 2024 | Epkinly |
| Beigene USA, INC. | $21.12 | 2024 | Brukinsa |
| Tempus Ai, INC | $20.15 | 2024 | |
| Boston Scientific Corporation | $19.61 | 2022 | |
| Astellas Pharma US INC | $19.47 | 2019 | |
| Mirati Therapeutics, INC. | $19.33 | 2024 | Krazati |
| Stemline Therapeutics INC. | $19.31 | 2024 | Orserdu |
| Kyowa Kirin, INC. | $18.85 | 2023 | Poteligeo |
| Bayer Healthcare Pharmaceuticals INC. | $18.07 | 2023 | |
| Daiichi Sankyo INC. | $17.29 | 2024 | Enhertu |
| Jazz Pharmaceuticals INC. | $17.15 | 2023 | Zepzelca |
| Array Biopharma INC | $15.39 | 2019 | |
| Taiho Oncology, INC. | $14.83 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Madani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.